# Capsida Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/capsida-biotherapeutics

- Industry: Biotechnology
- Headquarters: US
- Website: www.capsida.com
- Total disclosed funding: $50M
- Latest round: Series A (Apr 29, 2021)
- Investors on record: 2

## About

Capsida Biotherapeutics, Inc. focuses on developing targeted intravenous gene therapies for rare and common diseases, utilizing proprietary technology for efficient treatment delivery.Founded in 2019, Capsida Biotherapeutics, Inc. is a biopharmaceutical company based in the US, specializing in gene therapy innovations. The company was founded by Viviana Gradinaru, who has a background in neuroscience and previously contributed to research in gene delivery systems. Capsida has successfully completed a Series A funding round, securing USD 50.00 mn on April 29, 2021, led by investors Versant Ventures and Westlake Village BioPartners, which represents the total amount raised to date.Capsida Biotherapeutics specializes in developing targeted, intravenous (IV) gene therapies aimed at treating both rare and more common diseases. Their core offerings include investigational therapies for STXBP1 Developmental and Epileptic Encephalopathy (STXBP1-DEE), Parkinson’s Disease associated with GBA mutations (PD-GBA), and Friedreich’s Ataxia (FA). These therapies employ proprietary engineered capsids designed for high transduction levels in specific tissues, minimizing interactions with non-target organs. The company’s solutions aim to effectively cross the blood-brain barrier, ensuring innovative treatment options for patients across all demographics, supported by FDA IND clearance for clinical trials in the US.Capsida Biotherapeutics operates on a B2B model, partnering with leading biopharmaceutical companies to co-develop and commercialize its gene therapies. Revenue is anticipated through strategic collaborations with firms such as AbbVie, CRISPR Therapeutics, and Lilly’s Gene Therapy Division, alongside potential milestone payments and royalties. The company’s flagship products, including CAP-002 for STXBP1-DEE and CAP-003 for PD-GBA, are expected to generate revenue as they progress through clinical trials and commercialization, utilizing structures that involve upfront payments and royalty agreements based on future sales.Capsida Biotherapeutics plans to enhance its product pipeline and expand its market reach. The recent Series A funding of USD 50.00 mn will facilitate the opening of a new manufacturing facility, supporting the development of new therapies. The company aims to design and launch additional products targeting unmet medical needs in various regions, with a focus on North America and potentially other global markets in the coming years.

## Funding rounds

- Series A, Apr 29, 2021, $50M — Versant Ventures, Westlake Village BioPartners

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A
- Westlake Village BioPartners (https://capitalatlas.ai/funds/westlake-village-biopartners) — Series A